Streetbeat News

Stock Prices

STT

Barclays analyst Jason Goldberg has maintained an Overweight rating on State Street (NYSE:STT) and increased the price target from $87 to $102. This adjustment reflects a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:07 pm

BL

Piper Sandler analyst Brent Bracelin has downgraded BlackLine (NASDAQ:BL) from Neutral to Underweight while increasing the price target from $53 to $60. This suggests that while the analyst sees some upside potential in the stock's price, they believe the company may underperform the broader market or its sector.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:06 pm

CORT

KTRA

MIST

MOTS

RPID

The article lists the top 5 oversold health care stocks with potential for gains in January, based on their low Relative Strength Index (RSI) values. Corcept Therapeutics (CORT), Kintara Therapeutics (KTRA), Rapid Micro Biosystems (RPID), Motus GI Holdings (MOTS), and Milestone Pharmaceuticals (MIST) are identified as major oversold players in the sector, with RSI values near or below 30, indicating they may be undervalued.

Portfolio Pulse from Avi Kapoor

January 02, 2024 | 12:06 pm

SNDX

Syndax Pharmaceuticals announced recent updates and anticipated milestones for 2024, including the potential launch of two products in the U.S. The company also completed a $230M follow-on offering in December, which they believe extends their financial runway through 2026. They are currently working with the FDA on regulatory submissions.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:05 pm

BRK

BYDDF

NIO

TSLA

XPEV

Wang Chuanfu, CEO of BYD Co., has been praised by Charlie Munger for his manufacturing prowess, surpassing Elon Musk in this regard. BYD, a Chinese EV maker, is challenging Tesla's market dominance with its range of affordable electric vehicles. Warren Buffett's Berkshire Hathaway invested in BYD in 2008, recognizing its potential. BYD's success is also due to competition with other Chinese EV makers like Nio Inc and Xpeng Inc. The company is expanding globally and is expected to launch third-generation EVs next year.

Portfolio Pulse from Ramakrishnan M

January 02, 2024 | 12:05 pm

U

Piper Sandler analyst Brent Bracelin has downgraded Unity Software (NYSE:U) from Neutral to Underweight while increasing the price target from $20 to $35. This suggests that while the analyst sees some improvement in the company's valuation, there are still concerns that may affect the stock's performance.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:03 pm

AVDX

Piper Sandler analyst Brent Bracelin has downgraded AvidXchange Holdings (AVDX) from Overweight to Neutral, while increasing the price target from $12 to $13.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:02 pm

ROL

Rollins (NYSE:ROL) received mixed analyst ratings in the latest quarter, with 3 bullish and 1 indifferent rating. The average 12-month price target is $45.25, slightly up from the previous $45.00. Analysts from Goldman Sachs, Morgan Stanley, UBS, and Stifel provided recent evaluations, with price targets ranging from $40.00 to $50.00. Rollins, a global pest-control service provider, showed a revenue growth of 15.17% and a net margin of 15.2%, with an ROE of 10.45% and an ROA of 4.88%. The company maintains a low debt-to-equity ratio of 0.82.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 12:00 pm

BAC

Bank of America (NYSE:BAC) has received mixed analyst ratings over the past three months, with 7 analysts offering a range of opinions. The average 12-month price target is $40.56, up from $39.00, with high and low estimates of $51.00 and $30.00 respectively. Analysts from firms including Barclays, Odeon Capital, Goldman Sachs, Oppenheimer, Keefe, Bruyette & Woods, and BMO Capital have adjusted their ratings and price targets, reflecting their views on the company's market performance and financial health. Bank of America, a major U.S. financial institution, shows a positive revenue trend, strong net margin, but below industry average ROE and ROA, and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 12:00 pm

EXAS

Benchmark analyst Bruce Jackson upgraded Exact Sciences (NASDAQ:EXAS) from Hold to Buy and set a price target of $91.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 11:59 am